End-of-day quote
Oslo Bors
|
5-day change
|
1st Jan Change
|
- PTS
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21,356
|
23,372
|
8,287
|
6,988
|
5,153
|
-
|
-
|
Enterprise Value (EV)
1 |
21,356
|
21,490
|
6,164
|
5,327
|
3,904
|
4,147
|
5,153
|
P/E ratio
|
17.6
x
|
-307
x
|
-18.1
x
|
-16.8
x
|
-8.44
x
|
-7.56
x
|
-5.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
74.5
x
|
88.8
x
|
49.5
x
|
36.9
x
|
27
x
|
23.8
x
|
EV / Revenue
|
-
|
68.5
x
|
66.1
x
|
37.8
x
|
28
x
|
21.7
x
|
23.8
x
|
EV / EBITDA
|
-
|
-244
x
|
-11.4
x
|
-8.99
x
|
-5.8
x
|
-5.4
x
|
-4.35
x
|
EV / FCF
|
-
|
8,641
x
|
-25.5
x
|
-5.11
x
|
-5.85
x
|
-4.9
x
|
-3.58
x
|
FCF Yield
|
-
|
0.01%
|
-3.92%
|
-19.6%
|
-17.1%
|
-20.4%
|
-27.9%
|
Price to Book
|
-
|
-
|
5.11
x
|
3.85
x
|
4
x
|
4.83
x
|
-
|
Nbr of stocks (in thousands)
|
284,785
|
289,619
|
294,694
|
326,546
|
326,546
|
-
|
-
|
Reference price
2 |
74.99
|
80.70
|
28.12
|
21.40
|
15.78
|
15.78
|
15.78
|
Announcement Date
|
4/21/21
|
3/31/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.45
|
-
|
313.5
|
93.31
|
141.1
|
139.7
|
191.1
|
216.4
|
EBITDA
1 |
-98.76
|
-
|
-87.93
|
-542.7
|
-592.6
|
-673.4
|
-767.6
|
-1,186
|
EBIT
1 |
-98.89
|
-
|
-94.36
|
-549.3
|
-615.1
|
-698.9
|
-796.1
|
-1,224
|
Operating Margin
|
-794.57%
|
-
|
-30.1%
|
-588.66%
|
-435.95%
|
-500.4%
|
-416.55%
|
-565.5%
|
Earnings before Tax (EBT)
1 |
-95.96
|
-
|
-97.36
|
-526.9
|
-466.9
|
-643.8
|
-777.4
|
-1,251
|
Net income
1 |
-
|
1,249
|
-82.32
|
-441.7
|
-372.3
|
-612
|
-740.3
|
-1,251
|
Net margin
|
-
|
-
|
-26.26%
|
-473.34%
|
-263.86%
|
-438.2%
|
-387.36%
|
-578%
|
EPS
2 |
-0.3491
|
4.253
|
-0.2627
|
-1.550
|
-1.271
|
-1.870
|
-2.088
|
-2.813
|
Free Cash Flow
1 |
-
|
-
|
2.487
|
-241.5
|
-1,043
|
-667.6
|
-845.6
|
-1,439
|
FCF margin
|
-
|
-
|
0.79%
|
-258.79%
|
-739.52%
|
-477.98%
|
-442.49%
|
-665%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/15/20
|
4/21/21
|
3/31/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
278.3
|
33.2
|
13.02
|
34.1
|
33.3
|
54.2
|
30.31
|
24.14
|
10.99
|
40.64
|
44.58
|
44.58
|
EBITDA
1 |
132.5
|
-94.91
|
-197.4
|
-
|
-
|
-121.1
|
-148.4
|
-175.6
|
-162.7
|
-169.1
|
-167.3
|
-169.5
|
EBIT
1 |
128.8
|
-99.37
|
-202.1
|
-148.6
|
-
|
-126.9
|
-154.3
|
-181.6
|
-168.8
|
-175.4
|
-173.9
|
-176
|
Operating Margin
|
46.28%
|
-299.33%
|
-1,552.65%
|
-435.82%
|
-
|
-234.1%
|
-509.11%
|
-752.19%
|
-1,535.83%
|
-431.59%
|
-390.02%
|
-394.87%
|
Earnings before Tax (EBT)
1 |
133.9
|
-105.9
|
-194.9
|
-127.2
|
-
|
-108.7
|
-133.9
|
-100.2
|
-178
|
-160.1
|
-159.9
|
-163.3
|
Net income
1 |
94.31
|
-84.85
|
-151.2
|
-126.1
|
-
|
-97.9
|
-110.5
|
-56.53
|
-161.7
|
-153
|
-153
|
-156.3
|
Net margin
|
33.89%
|
-255.59%
|
-1,161.39%
|
-369.88%
|
-
|
-180.61%
|
-364.43%
|
-234.12%
|
-1,470.87%
|
-376.4%
|
-343.14%
|
-350.67%
|
EPS
2 |
-
|
-
|
-
|
-0.4134
|
-
|
-0.3188
|
-0.3235
|
-0.2118
|
-0.5410
|
-0.4675
|
-0.4605
|
-0.4640
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
8/23/22
|
11/23/22
|
2/28/23
|
5/12/23
|
8/22/23
|
11/15/23
|
2/28/24
|
5/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
1,882
|
2,123
|
1,661
|
1,249
|
1,005
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
2.49
|
-241
|
-1,043
|
-668
|
-846
|
-1,439
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-5.05%
|
-24.3%
|
-21.4%
|
-32.9%
|
-66.1%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-3.8%
|
-17.6%
|
-
|
-25.8%
|
-30.3%
|
-
|
Assets
1 |
-
|
-
|
2,167
|
2,516
|
-
|
2,372
|
2,443
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
5.510
|
5.550
|
3.950
|
3.270
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
27.6
|
20.1
|
16.2
|
14.5
|
43.3
|
Capex / Sales
|
-
|
-
|
-
|
29.62%
|
14.28%
|
11.62%
|
7.6%
|
20%
|
Announcement Date
|
4/15/20
|
4/21/21
|
3/31/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
15.78
NOK Average target price
43
NOK Spread / Average Target +172.50% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.91% | 114B | | +11.60% | 105B | | -4.68% | 23.83B | | -0.82% | 21.73B | | -10.12% | 18.1B | | -42.12% | 16.34B | | -17.47% | 16.13B | | +2.77% | 13.75B | | +34.58% | 11.76B |
Bio Therapeutic Drugs
|